Latest period
−$42.79M
YoY change
-11.5%
5Y CAGR
—
Peak year (2012)
−$7.57K
Latest annual
−$45.79M
Free Cash Flow history chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: −$45.79M
Free Cash Flow growth chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: -11.5%
Free Cash Flow history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| 2025 | −$45.79M | -11.5% | +$5.97M | ||
| 2024 | −$51.76M | +0.2% | −$96.59K | ||
| 2023 | −$51.66M | -50.2% | +$52.14M | ||
| 2022 | −$103.80M | +13.0% | −$11.93M | ||
| 2021 | −$91.87M | +230.4% | −$64.06M | ||
| 2020 | −$27.81M | +229876.9% | −$27.80M | ||
| 2019 | −$12.09K | -99.9% | +$10.49M | ||
| 2018 | −$10.50M | +74.5% | −$4.48M | ||
| 2017 | −$6.01M | -7.7% | +$501.56K | ||
| 2016 | −$6.52M | -52.5% | +$7.19M | ||
| 2015 | −$13.71M | -15.7% | +$2.54M | ||
| 2014 | −$16.25M | +118869.6% | −$16.24M | ||
| 2013 | −$13.66K | +80.6% | −$6.09K | ||
| 2012 | −$7.57K | — | — |
- 2025−$45.79M-11.5%
- 2024−$51.76M+0.2%
- 2023−$51.66M-50.2%
- 2022−$103.80M+13.0%
- 2021−$91.87M+230.4%
- 2020−$27.81M+229876.9%
- 2019−$12.09K-99.9%
- 2018−$10.50M+74.5%
- 2017−$6.01M-7.7%
- 2016−$6.52M-52.5%
- 2015−$13.71M-15.7%
- 2014−$16.25M+118869.6%
- 2013−$13.66K+80.6%
- 2012−$7.57K—
Free Cash Flow values are taken from Relmada Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Free Cash Flow at Relmada Therapeutics (RLMD)
Free Cash Flow for Relmada Therapeutics (RLMD): headline value −$42.79M · YoY -11.5%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Relmada Therapeutics (RLMD) reported free cash flow of −$45.79M – declined 11.5% year-over-year.
The record annual free cash flow stands at −$7.57K, reached in 2012; the historical low of −$103.80M was recorded in 2022.
Relmada Therapeutics Free Cash Flow by Year
Relmada Therapeutics Free Cash Flow 2025: −$45.79M
2025's free cash flow for Relmada Therapeutics came in at −$45.79M, declined 11.5% below 2024.
Relmada Therapeutics Free Cash Flow 2024: −$51.76M
Relmada Therapeutics posted free cash flow of −$51.76M in 2024, edged up 0.2% from 2023.
Relmada Therapeutics Free Cash Flow 2023: −$51.66M
In 2023, Relmada Therapeutics reported free cash flow of −$51.66M, plunged 50.2% below 2022.
Relmada Therapeutics Free Cash Flow 2022: −$103.80M
Relmada Therapeutics free cash flow in 2022 was −$103.80M, grew 13.0% from 2021. This figure represents the lowest annual value in the available history.
Relmada Therapeutics Free Cash Flow 2021: −$91.87M
Relmada Therapeutics free cash flow in 2021 was −$91.87M.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by Free Cash Flow
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest free cash flow
| $19.70B | |
| $17.82B | |
| $16.07B | |
| $12.36B | |
| $11.77B | |
| $8.97B | |
| $8.10B | |
| $4.52B |
- $19.70B
- $17.82B
- $16.07B
- $12.36B
- $11.77B
- $8.97B
- $8.10B
- $4.52B
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation